Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Hammersmith Hospital · Cancer Research UK · +25 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
908
total citations
- FWCI
- 59.92
- Percentile
- 100%
- References
- 22
Citations per year
Authors
34- RCR. Charles CoombesCorresponding
Hammersmith Hospital, Cancer Research UK, Imperial College London
- LKLucy Kilburn
Institute of Cancer Research
- CSCF Snowdon
Hammersmith Hospital, Cancer Research UK, Imperial College London
- RPRobert Paridaens
Universitair Ziekenhuis Leuven
- RCRE Coleman
Weston Park Cancer Centre
Topics & keywords
Topics
Keywords
- Exemestane
- Tamoxifen
- Medicine
- Hazard ratio
- Breast cancer
- Internal medicine
- Aromatase inhibitor
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.